Gilead's Antifungal Drug AmBisome® Launched in China for Invasive Fungal Diseases and Visceral Leishmaniasis

Gilead Sciences announced on June 3 that AmBisome® (Amphotericin B Liposome for Injection, 50mg) has officially launched in China. In February this year, Gilead's Amphotericin B Liposome for Injection was officially approved by the National Medical Products Administration for the treatment of invasive fungal diseases and visceral leishmaniasis.